Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial

Authors :: Shepherd, F. A.
Altorki, N. K.
Eberhardt, Wilfried
O'Brien, Mary
Spigel, D. R.
Crino, L.
Tsai, C. M.
Kim, J. H.
Cho, E. K.
Szczesna, A.
Burghuber, O.
Hoffman, P. C.
Keshavjee, S.
Orlov, S.
Serwatowski, P.
Wang, J. Z.
Foley, M. A.
Horan, J. D.
Richardson, F. C.
Kelly, K.
Tarceva Radiant Investigator Grp
Publication Year :: 2014
Abstract: 7513 Background: E, anEGFR TKI, prolongs survival in pts with advanced NSCLC. Pts with tumors carrying EGFR exon 19 del or 21 L858R mutations are particularly sensitive to EGFR TKIs. Methods: RADIA...

Tools